Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by M101on Sep 23, 2020 2:15pm
214 Views
Post# 31605245

vido intervac

vido intervac
Annayya brought up the Giovazzano-Nasdaq connection, and if you check out our new collaborator's website this seems logical as maybe Promis is finally starting to take seriously the advantages of establishing credibility in Canada's smaller and better regulated health care system. 

As I've said before on this board, and back in the AMF days, and to Golstein himself in a phone call years ago,  Cashman's work was once highlighted by the CBC (ok back in the BSE days) so why aren't we trying to raise his lab's profile again that way? E.g. on the science program Quirks and Quarks, which just happens to be linked to this week by ....Vido Intervac! https://www.vido.org/covid19

Elliot is not about to admit that his Nasdaq plans were premature if not simply too optimistic and just plain greedy. And his predecessor Gundel wouldn't admit it either.  BUT COULD IT GET ANY MORE OBVIOUS?
 



Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse